Business Description
Emergent BioSolutions Inc
NAICS : 325412
SIC : 2834
ISIN : US29089Q1058
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.23 | |||||
Equity-to-Asset | 0.34 | |||||
Debt-to-Equity | 1.3 | |||||
Debt-to-EBITDA | 32.32 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 1 | |||||
Beneish M-Score | -4.21 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -9.7 | |||||
3-Year Book Growth Rate | -23 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 19.02 | |||||
9-Day RSI | 34.42 | |||||
14-Day RSI | 41.51 | |||||
6-1 Month Momentum % | 84.72 | |||||
12-1 Month Momentum % | 464.62 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.88 | |||||
Quick Ratio | 1.47 | |||||
Cash Ratio | 0.65 | |||||
Days Inventory | 161.59 | |||||
Days Sales Outstanding | 47.75 | |||||
Days Payable | 49.07 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.6 | |||||
Shareholder Yield % | 68.82 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 31.6 | |||||
Operating Margin % | -10.58 | |||||
Net Margin % | -19.08 | |||||
FCF Margin % | 12.62 | |||||
ROE % | -35.94 | |||||
ROA % | -12.27 | |||||
ROIC % | -9.36 | |||||
ROC (Joel Greenblatt) % | -13.89 | |||||
ROCE % | -8.04 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 2.87 | |||||
Price-to-Owner-Earnings | 93.15 | |||||
PS Ratio | 0.42 | |||||
PB Ratio | 0.91 | |||||
Price-to-Free-Cash-Flow | 3.47 | |||||
Price-to-Operating-Cash-Flow | 2.78 | |||||
EV-to-EBIT | -10.63 | |||||
EV-to-EBITDA | 47.66 | |||||
EV-to-Revenue | 0.89 | |||||
EV-to-Forward-Revenue | 1.5 | |||||
EV-to-FCF | 7.08 | |||||
Price-to-Projected-FCF | 0.6 | |||||
Price-to-Median-PS-Value | 0.12 | |||||
Earnings Yield (Greenblatt) % | -9.41 | |||||
FCF Yield % | 29.74 | |||||
Forward Rate of Return (Yacktman) % | 37.52 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:EBS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Emergent BioSolutions Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 1,094.2 | ||
EPS (TTM) ($) | -4.1 | ||
Beta | 2.45 | ||
Volatility % | 239.93 | ||
14-Day RSI | 41.51 | ||
14-Day ATR ($) | 0.616597 | ||
20-Day SMA ($) | 9.225 | ||
12-1 Month Momentum % | 464.62 | ||
52-Week Range ($) | 1.42 - 15.1 | ||
Shares Outstanding (Mil) | 54.18 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Emergent BioSolutions Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Emergent BioSolutions Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Emergent BioSolutions Inc Frequently Asked Questions
What is Emergent BioSolutions Inc(EBS)'s stock price today?
When is next earnings date of Emergent BioSolutions Inc(EBS)?
Does Emergent BioSolutions Inc(EBS) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |